Pharmacy NNN Investments in 2026: Navigating the CVS, Walgreens, and Rite Aid Landscape

For decades, pharmacy and drug store chains were considered the gold standard of net lease investing — long-term leases, investment-grade tenants, and recession-resistant demand driven by an aging population and prescription drug dependency. But as the industry enters 2026, that narrative has grown considerably more complex. A widening divergence in credit quality, store closure programs, and shifting consumer behavior have created both risk and opportunity for NNN investors willing to look closely at the fundamentals.

A Sector Defined by Divergence

Perhaps no single data point captures the current state of pharmacy net lease better than the pricing spread between the sector’s two dominant players. As of early 2026, the cap rate gap between CVS and Walgreens properties has reached a historically wide 130 basis points — a record differential that reflects dramatically different investor sentiment toward each chain. This spread is now the widest of any single-tenant category across the entire net lease market, signaling that investors are treating these two banners as fundamentally different risk profiles despite their surface-level similarities.

CVS continues to command premium pricing, trading at tighter cap rates consistent with investment-grade confidence. Walgreens, by contrast, has seen its cap rates push outward as the market prices in ongoing operational challenges, lease restructuring activity, and questions about long-term store viability. For investors, this divergence means due diligence on the specific tenant — not just the asset class — has never mattered more.

Walgreens: Headwinds and Opportunities

Walgreens has been navigating a turbulent period, including store rationalization efforts and pressure on its core retail pharmacy model. As a result, cap rates on Walgreens NNN properties have drifted higher, which creates an interesting dynamic: for risk-tolerant investors, the yield premium available on well-located Walgreens assets may offer compelling entry points that more cautious buyers are leaving on the table. Location quality, lease term remaining, and co-tenancy context are all critical variables when evaluating these opportunities.

The key question for any Walgreens acquisition in 2026 centers on real estate fundamentals independent of the tenant. Is the site a high-traffic corner with strong demographics? Would the box attract alternative users if the tenancy changed? These questions have always mattered in net lease, but they matter considerably more when the tenant’s credit profile is under scrutiny.

CVS: Relative Stability in a Shifting Market

CVS has maintained stronger investor confidence heading into 2026, supported by its more diversified healthcare services strategy, including its insurance and pharmacy benefit management operations. That diversification has helped insulate the brand from some of the pure retail pharmacy headwinds affecting competitors. Tighter cap rates on CVS product reflect this institutional appetite, though buyers should still scrutinize lease structure, remaining term, and any co-tenancy or termination option clauses embedded in older leases.

Rite Aid: A Cautionary Tale

Rite Aid’s ongoing financial restructuring has effectively removed it from consideration as a core NNN holding for most institutional and private investors. Properties encumbered by Rite Aid leases now require a fundamentally different underwriting lens — one focused almost entirely on real estate utility and re-tenanting potential rather than lease income reliability. The Rite Aid situation serves as a broader reminder that investment-grade status is not a permanent condition, and that pharmacy NNN investors must continuously reassess tenant credit alongside property fundamentals.

What Investors Should Focus On in 2026

Credit stratification: Treat CVS, Walgreens, and Rite Aid as three distinct investment categories, not a unified “pharmacy” sector.
Real estate quality: Prioritize freestanding, high-visibility corner locations with strong traffic counts and favorable demographics regardless of tenant.
Lease structure: Scrutinize remaining lease term, rent escalation schedules, and any embedded options that could affect income predictability.
Alternative use value: In a higher-cap-rate environment, the value of a property as a re-tenantable box is a meaningful component of underwriting.
Spread opportunity: The historic 130 bps CVS-Walgreens gap presents a strategic decision point — premium safety versus enhanced yield — that should align with each investor’s specific risk tolerance and portfolio objectives.

Pharmacy net lease in 2026 is not a monolithic category. It is a nuanced market where informed investors can find either stability or yield — depending on which chain, which location, and which lease structure they choose to underwrite. The divergence defining this sector today is not a temporary anomaly; it is a structural repricing that rewards careful analysis over broad category assumptions.

Sources

CoStar Group — Net Lease Market Research, Early 2026 (costar.com)
Stan Johnson Company / SRS Real Estate Partners — Net Lease Research Reports, Q1 2026
The Boulder Group — Net Lease Research Reports, Q1 2026 (bouldergroup.com)
CBRE — U.S. Net Lease Investment Trends, 2026 (cbre.com)
Walgreens Boots Alliance — Public Filings and Press Releases, 2025–2026 (investor.walgreensbootsalliance.com)
CVS Health — Investor Relations and Annual Reports, 2025–2026 (investors.cvshealth.com)
Rite Aid Corporation — Bankruptcy and Restructuring Public Filings, 2024–2026